Genetic Testing for Opioid Risk: The AvertD Post-Approval Study

Prescient Medicine Holdings, Inc. is conducting an important observational study called the AvertD Post-Approval Study to evaluate the effectiveness of genetic testing in identifying patients at risk for developing opioid use disorder. This research is particularly significant as it focuses on individuals who are being considered for their first prescription of oral opioid medications, typically prescribed for pain management following surgeries, injuries, or medical procedures.

The study aims to enroll approximately 4,000 adult participants who will undergo genetic testing using the AvertD risk assessment tool. This innovative approach seeks to identify genetic markers that may indicate a predisposition to opioid use disorder before patients begin opioid therapy. Participants must be willing to commit to yearly assessments over a five-year period, allowing researchers to track long-term outcomes and the accuracy of the genetic risk prediction.

For patients and caregivers considering participation, the eligibility criteria include being at least 18 years old, facing a first-time opioid prescription of 4-30 days duration, and having the AvertD test prescribed as part of their standard care. The study excludes those with planned opioid prescriptions shorter than 4 days or longer than 30 days, as well as individuals with conditions that might make participation unsafe.

The primary goal of this research is to measure the sensitivity and specificity of the AvertD genetic test by comparing its results with actual diagnoses of opioid use disorder using the M.I.N.I. diagnostic tool over the five-year study period. This validation process is crucial for ensuring that the test provides accurate risk assessments that can genuinely help healthcare providers make informed decisions about pain management strategies.

This study represents a significant advancement in personalized medicine and preventive healthcare. By identifying individuals at higher genetic risk for opioid use disorder before they begin opioid therapy, healthcare providers can implement additional safeguards, consider alternative pain management options, or provide more intensive monitoring for those at elevated risk. The collaboration between Prescient Medicine, Concentrics Research, and Caron Treatment Centers brings together expertise in genetic testing, clinical research, and addiction treatment to address one of today's most pressing public health challenges.

The opioid crisis has devastating effects on individuals, families, and communities across the nation. Research like the AvertD study is critical for developing tools that can help prevent addiction before it starts. Genetic risk assessment represents a promising approach to addressing this complex issue, potentially saving countless lives and reducing the social and economic costs associated with opioid addiction. For patients and caregivers, participation in such studies contributes to medical knowledge that may ultimately lead to better, safer pain management practices for everyone.

Clinical trials focusing on preventive measures and early intervention are essential components of modern healthcare research. They help bridge the gap between scientific discovery and practical clinical applications that directly benefit patients. Studies that incorporate genetic testing particularly highlight the growing importance of personalized medicine, where treatments and preventive strategies can be tailored to individual genetic profiles rather than applying one-size-fits-all approaches.